Working… Menu
Trial record 63 of 272 for:    Betamethasone

Impact of Antenatal Betamethasone on Plasma Glucose Levels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00585676
Recruitment Status : Completed
First Posted : January 3, 2008
Last Update Posted : February 27, 2019
University of Washington
Information provided by (Responsible Party):
Deborah A. Wing, University of California, Irvine

Brief Summary:
It is known that administration of steroids increases blood sugar levels. Administration of betamethasone is common practice during pregnancy to women at risk for preterm delivery. However, it is unknown the magnitude of the changes in glucose these women have after receiving betamethasone. The purpose of this study is to determine the magnitude and timing of the increase in blood sugar in pregnant women without diabetes who receive steroids.

Condition or disease

Detailed Description:

There is a substantial body of evidence that the administration of corticosteroids to patients deemed to be at risk for preterm delivery (delivery prior to 37 weeks gestation) decreases the risk of respiratory distress syndrome, intraventricular hemorrhage, and neonatal death. Current recommendations from the National Institute of Health (NIH) and the American College of Obstetricians and Gynecologists (ACOG) are that patients with pregnancies that are between 24-34 weeks gestation deemed at risk for preterm delivery receive antenatal corticosteroids. The recommended dosing is two doses of betamethasone 12 mg given 24 hours apart as an intramuscular injection. (Alternatively, dexamethasone 6 mg given intramuscularly every 6 hours for 4 doses may be administered. Betamethasone is used preferentially in our institution.)

Glucocortiocoids have a well-known effect on glucose metabolism. They increase blood glucose levels by antagonizing insulin and decreasing synthesis of insulin, thus inhibiting peripheral glucose utilization and increasing gluconeogenesis (the process by which the body produces glucose). Pregnancy is also characterized by a relative insulin resistance that results in glucose intolerance. It follows, then, that the combination of pregnancy and corticosteroids could cause significant disruption of glucose homeostasis.

Routinely in pregnancy, gestational diabetes is diagnosed by the administration of a glucose tolerance test consisting of ingestion of 50g of glucose followed by a serum glucose level one hour later. This is known as a one-hour post-glucola test. A value of 140 mg/dL is considered abnormal, and prompts administration of the 3-hour glucose tolerance test. This test consists of a fasting blood sugar, followed by serum glucose levels after a 100g oral glucose challenge at 1-, 2- and 3-hours. A profile with two or more abnormal values is considered diagnostic for gestational diabetes. In 1997 Fisher et al retrospectively compared the incidence of gestational diabetes in those patients who had received tocolytics and antenatal corticosteroids to those who did not, and found a higher incidence of both abnormal one-hour glucose screening tests and gestational diabetes in those patients who received steroids and tocolytics (medications used to try to decrease uterine contractions). However, the interval between the receipt of steroids and the administration of the glucose screening test was quite variable in this study. Shelton et al in 2002 evaluated the extent of hyperglycemia in non-diabetic patients who received multiple weekly doses of corticosteroids. They found that the fasting glucose levels increased for several days following the first course of steroids, returned to normal, and then remained persistently elevated in those patients who received three or more courses. Postprandial levels were not significantly altered. A study by Gurbuz et al in 2003 assessed the effects of betamethasone on the one-hour glucola test and found that although there was an initial effect on the screening test, this effect was transient and resolved generally one week after the administration of the second dose of betamethasone. These patients had a one-hour screening test performed prior to the administration of corticosteroids. The dosing regimen of betamethasone, however, was different from that recommended by ACOG. Thus far, no study has reported if: (1) there is significant hyperglycemia in non-diabetic patients who receive corticosteroids and (2) how the magnitude and pattern of the increase in glucose differs in patients with normal and abnormal one-hour glucolas or with diabetes. This study will be conducted as a pilot study, as there is no reports of the extent of hyperglycemia that occurs in non-diabetic patients after administration of corticosteroids to guide a sample size calculation. We will plan to obtain thirty non-diabetic subjects with fifteen diet-controlled diabetic controls for comparison. The hypothesis is that those patients that are not diabetic will not have the same extent of hyperglycemia as those who are diabetic.

Layout table for study information
Study Type : Observational
Actual Enrollment : 45 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Antenatal Betamethasone on Plasma Glucose Levels
Study Start Date : November 2007
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hyperglycemia

Patients with Diabetes
Abnormal glucose level
Patients who were screened and had abnormal blood glucose levels
Non-diabetic (normal glucose screening)

Primary Outcome Measures :
  1. Area under the curve of blood glucose [ Time Frame: 5 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Pregnant women receiving corticosteroids

Inclusion criteria:

  • Candidates for antenatal corticosteroids (including gestational age between 24-34 weeks)

Exclusion criteria:

  • Age less than 18 years
  • Pre-existing maternal corticosteroid or beta-mimetic tocolytic use
  • Pre-gestational diabetes mellitus, class C or greater
  • Pre-existing adrenal or pancreatic dysfunction
  • Evidence of infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00585676

Layout table for location information
United States, California
Miller Children's Hospital
Long Beach, California, United States, 90806
Sponsors and Collaborators
University of California, Irvine
University of Washington
Layout table for investigator information
Principal Investigator: Michael P Nageotte, MD Miller Children's Hospital

Layout table for additonal information
Responsible Party: Deborah A. Wing, Professor and Director, Maternal-Fetal Medicine, University of California, Irvine Identifier: NCT00585676     History of Changes
Other Study ID Numbers: 436-07
First Posted: January 3, 2008    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: February 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Betamethasone Valerate
Betamethasone benzoate
Betamethasone sodium phosphate
Glucose Metabolism Disorders
Metabolic Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents